ATC codes:
H02AB02
EMLc
Indication
Lymphoid leukaemia, not elsewhere classified
ICD11 code:
2C03.3
INN
Dexamethasone
Medicine type
Chemical agent
List type
Complementary
(EML)
(EMLc)
(EMLc)
Formulations
Oral > Liquid:
2 mg per 5 mL
(EMLc)
Oral > Solid: 2 mg (EMLc) ; 4 mg
Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
Oral > Solid: 2 mg (EMLc) ; 4 mg
Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Read more
about patents.
Summary of evidence and Expert Committee recommendations
In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for asparaginase on the complementary list of the EML and EMLc for use in treatment protocols for acute lymphoblastic leukaemia (ALL) was recommended. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for ALL is attached.